Xstim

What Xstim does

Xstim, Inc. is a privately held, U.S.-based medical device company that develops and sells the Xstim Spine Fusion Stimulator, an FDA Class 3-approved prescription device (PMA P230025, approved 2023) that uses capacitive coupling technology to deliver imperceptible low-level electrical impulses to the lumbar spine, upregulating bone morphogenetic proteins to promote fusion healing after one- or two-level lumbar spinal fusion surgery. The device is a compact, lightweight wearable with an onboard HD screen, hydrogel electrodes placed adjacent to the fusion site, rechargeable batteries, and a 270-day (9-month) continuous-use treatment course, with the therapy backed by 30+ years of clinical evidence including a double-blind study showing an 84.7% fusion success rate versus 64.9% for placebo (Goodwin et al., 1999) and a recommendation from the North American Spine Society for posterolateral fusions.

The company generates revenue through prescription-based hardware sales to patients via orthopedic and spine surgeons, supplemented by recurring replacement-supply purchases — electrodes are replaced every 1 to 7 days, with rechargeable batteries and accessories replenished across the treatment course. Pricing is not publicly disclosed but the device is covered by Medicare, Medicaid, workers' compensation, and private/public health plans, with third-party billing partners assisting patients with coverage verification. The company operates a concierge care model that delivers personalized product training, dedicated provider liaison coordination, insurance navigation, and ongoing patient progress monitoring.

Xstim is headquartered in Irving, Texas (1231 Greenway Dr. Suite 260), is incorporated in Delaware, and has recently been acquired by EBI (Electro-Biology, Inc.), joining the most comprehensive portfolio of bone growth stimulation solutions. The company sells exclusively in the United States, has a small employee base (1-10), and operates a single-product, enterprise field sales go-to-market motion targeting healthcare providers who prescribe the device for lumbar fusion adjunct therapy.

Name

Xstim

Legal name

Xstim, Inc.

Website

https://xstimmed.com

Company type

Private

Operating status

Acquired

Headcount range

1–10 employees

Short description

Xstim is a U.S. medical device company that sells the FDA-approved Xstim Spine Fusion Stimulator, a capacitive coupling wearable for bone growth stimulation after one- or two-level lumbar spinal fusion surgery, prescribed by orthopedic and spine surgeons and now part of EBI.

Ownership category

akta.pro rank

Product category

Orthopedic Bone Growth Stimulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro industry

PRIMARYHLAHAEAC

Spine Implants & Motion Preservation (Fusion/Disc/Interspinous)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

• Bone growth stimulation
• Spinal fusion therapy
• Capacitive coupling technology
• Orthopedic medical devices
• Postoperative bone healing

Headquarters

HQ city

Irving

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Medical Device Sales: Xstim Spine Fusion Stimulator is a Class 3 FDA-approved medical device sold as a prescription-only product. The company generates revenue through device sales to patients via healthcare provider prescriptions, with ongoing revenue from replacement supplies including electrodes (replaced every 1-7 days), rechargeable batteries, and accessories. Treatment course is 270 days (approximately 9 months). Insurance coverage is available through Medicare, Medicaid, worker's compensation, and private/public health plans via third-party billing services.
2. Replacement Supplies and Accessories: Ongoing revenue from consumable supplies including electrodes, batteries, and accessory components that patients need throughout their 270-day treatment course

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Xstim develops and sells the Xstim Spine Fusion Stimulator, a Class 3 FDA-approved (PMA P230025) wearable medical device that uses capacitive coupling technology to deliver imperceptible low-level electrical pulses to the lumbar spine fusion site, promoting bone healing after one- or two-level lumbar spinal fusion surgery. The device is sold prescription-only through healthcare providers, with a 270-day treatment course, replacement hydrogel electrodes and rechargeable batteries, and concierge care support for both providers and patients.

Product overview

Xstim offers a single flagship product - the Xstim Spine Fusion Stimulator - which is a Class 3 FDA-approved bone growth stimulation medical device. The product portfolio consists of the main stimulator unit along with its accessories (hydrogel electrodes, rechargeable batteries, charger, carrying case, belt clip, and electrode lead wires). The device utilizes capacitive coupling technology to transmit low-level electrical pulses to the fusion site, promoting bone healing with a clinically proven success rate of up to 85%.

Differentiator

Problem solved

Functional benefit

Products and services

• Xstim Spine Fusion Stimulator

Quantifiable outcome

• Up to 85% clinical success rate in one- or two-level lumbar fusion surgery patients
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• EBI (Electro-Biology, Inc.)coreOthersXstim has joined EBI, becoming part of the most comprehensive portfolio of bone growth stimulation solutions. This affiliation provides access to EBI's established bone growth stimulation portfolio and resources.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Medtronic: Medtronic is the dominant player in the broader spine surgery market (hardware, biologics, and intraoperative imaging). Its scale and surgeon relationships create category-level competitive pressure on adjunct bone healing devices like Xstim, even when it does not market a direct capacitive coupling substitute.
• Zimmer Biomet: Zimmer Biomet is a major orthopedic device manufacturer with spine-related biologics and a large surgeon sales force. It competes indirectly with Xstim by serving the same prescribers and offering post-fusion recovery products.
• Smith+Nephew: Smith+Nephew is a global orthopedic medical device manufacturer with a presence in biologics, joint reconstruction, and sports medicine. While it does not lead in capacitive coupling BGS, its orthopedic sales infrastructure competes for the same clinical and reimbursement budget pool that Xstim targets.
• Stryker: Stryker operates a large spine and orthopedic implant business with extensive sales coverage. Although it is not a BGS pure-play, Stryker could bundle or develop competing adjunct therapies within its spine portfolio.
• Globus Medical (formerly SeaSpine): Globus Medical, post-merger with SeaSpine, is a leading spine-focused medical device company selling implants, biologics, and capital equipment to spine surgeons. While it does not market a competitive electrical stimulator, it represents an alternative channel/market participant in spinal fusion solutions.

Direct peers

• Bioventus: Bioventus markets the EXOGEN ultrasound bone healing system for fracture non-union and is active in bone healing adjacencies. While modality (ultrasound vs capacitive coupling) differs, Bioventus competes for the same prescribers and orthobiologics budgets as Xstim.
• Orthofix Medical: Orthofix is the most established competitor in spinal bone growth stimulation, with PEMF-based SpinalStim and CervicalStim devices indicated as adjuncts to spinal fusion. It competes head-to-head with Xstim in the same patient indication, prescriber base (spine surgeons), and reimbursement environment.
• Enovis Corporation (formerly DJO): Enovis has historically marketed bone growth stimulation devices (e.g., CMF OL1000) and is a major orthopedic and post-surgical rehabilitation platform. It overlaps with Xstim in bone growth stimulation technology and in selling to spine/orthopedic surgeons.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xstim